These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 30962677)

  • 1. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
    Sidharta PN; Melchior M; Kankam MK; Dingemanse J
    Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects.
    Fontes MSC; Dingemanse J; Sidharta PN
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):718-725. PubMed ID: 33063477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
    Sidharta PN; Dingemanse J
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
    Sidharta PN; Ulč I; Dingemanse J
    Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet.
    Gueneau de Mussy P; Sidharta PN; Wuerzner G; Maillard MP; Guérard N; Iglarz M; Flamion B; Dingemanse J; Burnier M
    Clin Pharmacol Ther; 2021 Mar; 109(3):746-753. PubMed ID: 32897570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
    Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
    Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension.
    Brussee JM; Sidharta PN; Dingemanse J; Krause A
    J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):243-252. PubMed ID: 38332190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.
    Fontes MSC; Dingemanse J; Halabi A; Tomaszewska-Kiecana M; Sidharta PN
    Sci Rep; 2022 Nov; 12(1):19067. PubMed ID: 36352054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects.
    Sidharta PN; Dingemanse J
    Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):227-234. PubMed ID: 31773427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macitentan: entry-into-humans study with a new endothelin receptor antagonist.
    Sidharta PN; van Giersbergen PL; Halabi A; Dingemanse J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):977-84. PubMed ID: 21541781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.
    Sidharta PN; van Giersbergen PL; Wolzt M; Dingemanse J
    Br J Clin Pharmacol; 2014 Nov; 78(5):1035-42. PubMed ID: 24962473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
    Sidharta PN; van Giersbergen PL; Dingemanse J
    J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans.
    Sidharta PN; Fischer H; Dingemanse J
    Curr Drug Metab; 2021; 22(5):399-410. PubMed ID: 33563190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults.
    Nussbaum JC; Hussain A; Butera P; Ford AP; Kitt MM; O'Neill EA; Smith S; Vargas G; O'Reilly T; Wynne C; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2024 Aug; 64(8):1023-1029. PubMed ID: 38651193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man.
    Dieterle W; Mann J; Kutz K
    Int J Clin Pharmacol Ther; 2005 Apr; 43(4):178-86. PubMed ID: 15966464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension.
    Angeli F; Verdecchia P; Reboldi G
    Cardiol Ther; 2021 Dec; 10(2):397-406. PubMed ID: 34251649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.
    Verweij P; Danaietash P; Flamion B; Ménard J; Bellet M
    Hypertension; 2020 Apr; 75(4):956-965. PubMed ID: 32063059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
    van Giersbergen PL; Dingemanse J
    Eur J Clin Pharmacol; 2007 Feb; 63(2):151-8. PubMed ID: 16636870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.
    Lindegger N; Sidharta PN; Reseski K; Dingemanse J
    Pulm Pharmacol Ther; 2014 Oct; 29(1):41-8. PubMed ID: 24813561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.